Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 3
4(100.0%)
4Total
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06134167Phase 3Recruiting

A Study to Evaluate the Safety and Effectiveness Transdermal Compress Device in Participants With Transfemoral Amputations

Role: lead

NCT03717506Phase 3Completed

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

Role: lead

NCT03091777Phase 3Completed

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

Role: lead

NCT02952898Phase 3Completed

Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

Role: lead

All 4 trials loaded